Saturday, October 31, 2026

Ripple On Bearish Momentum: 9.26% Down In The Last 6 Hours

ViaNews Editorial Team

December 23, 2020

Ripple On Bearish Momentum: 9.26% Down In The Last 6 Hours

Ripple is currently on bearish momentum. At 20:06 EST on Tue 22 Dec, Ripple is at $0.43 and down by 9.26% in the last 6 hours.

Ripple Range

Over the last six hours, Ripple's higher value was $0.47 and the lower value was $0.43.

Over the last twelve hours, Ripple's higher value was $0.49 and the lower value was $0.43.

In relation to Ripple's daily highs and lows, it's 0.419% up from its trailing 24-hour low of $0.43 and 11.878% down from its trailing 24-hour high of $0.49.

Concerning Ripple's yearly highs and lows, it's 275.152% up from its 52-week low and 43.776% down from its 52-week high.

Last news about Ripple

Ripple to face SEC suit over XRP cryptocurrency. According to The Wall Street Journal on Tue Dec 22, "Ripple said it was informed by the commission on Monday that regulators soon plan to sue the company, Chief Executive Brad Garlinghouse and co-founder Chris Larsen in federal civil court. ", "None of those companies, though, was as big as Ripple and XRP. "

Cryptocurrency firm ripple expects to be sued by the sec; XRP plunges. According to CNBC on Tue Dec 22, "The "security" label matters because it could bring XRP under strict new rules, and that could heavily impact Ripple. ", "The fresh scrutiny over Ripple comes days after the Treasury Department proposed a new bitcoin disclosure rule aimed at closing money-laundering regulatory gaps. "

Ripple says it faces SEC lawsuit as cryptocurrency XRP drops. According to Bloomberg Quint on Tue Dec 22, "XRP, the world's third-largest cryptocurrency, slumped after Ripple Labs Inc. said it faces a U.S. Securities and Exchange Commission lawsuit over its affiliated token.", "Ripple earlier this year also failed to persuade a judge to throw out a proposed class-action lawsuit accusing the company of selling unregistered securities."

Ripple labs, executives sued by SEC for failing to register XRP. According to Bloomberg Quint on Tue Dec 22, "On Monday, the CEO disclosed that the regulators had "inexplicably decided to sue Ripple" but he didn't specify the nature of the allegations. ", ""Ripple used this money to fund its operations without disclosing how it was doing so, or the full extent of its payments to others to assist in its efforts to develop a 'use' for XRP and maintain XRP secondary trading markets.""

News about Bitcoin

Elon Musk inquired on twitter about 'large' Bitcoin transactions after a crypto booster suggested he convert Tesla's balance sheet. According to Business Insider on Mon Dec 21, "Before the exchange with Saylor, he tweeted "Bitcoin is my safe word," but then followed up by saying, "Just kidding, who needs a safe word anyway!?"", "Following the Saylor conversation, Musk tweeted: "Bitcoin is almost as bs as fiat money," and then suggested to his followers he's a fan of Dogecoin, a parody cryptocurrency."

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com